Abstract
Bone metastasis of breast cancer often presents as osteolytic. 177 Lu-DOTA-ibandronic acid ( 177 Lu-DOTA-IBA) is a new radioactive drug for bone metastasis lesion. We report a case of recurrent intermittent pain due to bone metastasis, who demonstrated a satisfactory therapy response after 2 cycles of 177 Lu-DOTA-IBA. In addition, the patient did not have any observable adverse effects.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
